Tuesday, June 18, 2013 3:14:27 PM
Posted by: Shayan Afkhami Posted date: June 18, 2013 In: Analyst Articles - US, Investing
Tekmira Pharmaceuticals Corp (NASDAQ: TKMR)‘s stock had its “buy” rating reaffirmed by research analysts at Maxim Group in a report released on Tuesday, TheFlyOnTheWall.com reports. They currently have a $7.00 price target on the stock. Maxim Group’s price objective would suggest a potential upside of 45.83% from the stock’s previous close.
Shares of Tekmira Pharmaceuticals Corp (NASDAQ: TKMR) traded down 1.25% during mid-day trading on Tuesday, hitting $4.74. Tekmira Pharmaceuticals Corp has a one year low of $1.77 and a one year high of $6.78. The stock’s 50-day moving average is currently $4.55.
Tekmira is a leader in the development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (NASDAQ: TKMR).
http://www.mideasttime.com/tekmira-pharmaceuticals-corps-buy-rating-reaffirmed-at-maxim-group-tkmr/26169/
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM